glp-1 psoriatic arthritis Which PsO Patients Can Benefit From GLP-1RAs? glp-1 psoriatic arthritis receptor agonists:

Patients with a history of allergic reactions or sensitivities to GLP-1 receptor agonists, pancreatitis, thyroid cancerincluding medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2) generally are not suitable candidates for this therapy

The direct consequence of such a high dose is that the potency of the GLP-1 peptide component in the fusion had to be appropriately reduced to try minimising GLP-1-induced gastrointestinal side effects 18

Nonetheless, the overall impact on body weight remained less than strictly additive

Concerning mPGES-2s, they were initially not considered as GSTs because GSH was not absolutely required for the detected activity e.g., the isomerization of ProstaGlandin H 2 (PGH 2 ) (Tanikawa et al., 2002) and because they exhibited a low similarity with GSTs identified at that time